Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.

Trial Profile

Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms ZEUS
  • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2011 Status changed from recruiting to active, no longer recruiting, as reported by the 53rd AMEASH
    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top